COGNITION THERAPEUTICS INC. - COMMON STOCK

Cognition Therapeutics Announces Participation in March Investment Conferences

08 Mar 2022 07:00:02 By Nasdaq GlobeNewswire

Cognition Therapeutics to Participate in Panel during the BIO CEO & Investor Conference on the Development of Neurodegenerative Therapeutics

08 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022

10 Jan 2022 06:30:01 By Nasdaq GlobeNewswire

Cognition Therapeutics Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinson’s Disease

04 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics to Participate in Next-Generation Alzheimer’s Disease Panel at Virtual Biotech Showcase on January 11, 2022

21 Dec 2021 06:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics to Host Virtual R&D Symposium December 7 on Dementia with Lewy Bodies and the Potential for Sigma-2 Modulation

30 Nov 2021 06:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in connection with Initial Public Offering

15 Nov 2021 06:30:01 By Nasdaq GlobeNewswire

Cognition Therapeutics Adds Public Company Financial and Operational Expertise to Board of Directors with Appointment of Ellen B. Richstone

03 Nov 2021 07:00:03 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Pricing of Upsized Initial Public Offering

08 Oct 2021 06:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Launch of its Initial Public Offering

04 Oct 2021 06:54:24 By Nasdaq GlobeNewswire